» Articles » PMID: 39906838

Anti-PL-7/PL-12 Antisynthetase Syndrome Associated with Interstitial Lung Disease Following SARS-COV-2 Infection and Vaccination: A Case Study Review

Abstract

Cumulative evidence suggests a link between specific autoimmune diseases (AD), including idiopathic inflammatory myopathies (IIM), and SARS-CoV-2 infection or COVID-19 vaccination. Anti-synthetase syndrome (ASS), a subset of IIM, is defined by the presence of autoantibodies against aminoacyl-tRNA synthetase (anti-ARS) and is strongly associated with interstitial lung disease (ILD), a major contributor to severe complications and reduced survival. We present four clinical cases of patients who developed autoantibodies against threonyl (PL-7) and alanyl (PL-12) synthetases associated with ASS-ILD shortly after SARS-CoV-2 infection or COVID-19 vaccination. Anti-ARS autoantibodies were identified using three complementary methods: immunoblotting, western blotting (WB) and the method considered the gold standard, immunoprecipitation (IP), which ensures accurate interpretation of results. The study highlights the clinical and pathogenic overlap between ASS-ILD and SARS-CoV-2-related lung involvement.Both conditions share similar high-resolution computed tomography (HRCT) patterns, including inflammation and pulmonary fibrosis (PF), driven by IFN-γ signaling, which complicates accurate diagnosis. Our results provide novel insights into the temporal association of SARS-CoV-2 and vaccine exposure with ASS-ILD, focusing on possible molecular mimicry between viral proteins and ARS molecules as a potential mechanism. Understanding the involvement of specific anti-ARS autoantibodies (PL-7 and PL-12) and the identification of genetic predispositions (HLA-B∗08:01 and HLA-DRB1∗03:01) in these patients may be key to underpinning these autoimmune manifestations. The study underscores the importance of a multidisciplinary approach and vigilant follow-up to optimize diagnosis and management. Further research is essential to elucidate the causal relationships and molecular mechanisms behind these observations.

References
1.
Baratella E, Marrocchio C, Cifaldi R, Santagiuliana M, Bozzato A, Crivelli P . Interstitial lung disease in patients with antisynthetase syndrome: a retrospective case series study. Jpn J Radiol. 2020; 39(1):40-46. PMC: 7813732. DOI: 10.1007/s11604-020-01030-3. View

2.
Elsayed M, Abdelgabar A, Karmani J, Majid M . A Case of Antisynthetase Syndrome Initially Presented With Interstitial Lung Disease Mimicking COVID-19. J Med Cases. 2023; 14(1):25-30. PMC: 9881486. DOI: 10.14740/jmc4031. View

3.
George P, Wells A, Gisli Jenkins R . Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020; 8(8):807-815. PMC: 7228727. DOI: 10.1016/S2213-2600(20)30225-3. View

4.
Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C . Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012; 11(10):739-45. DOI: 10.1016/j.autrev.2012.01.006. View

5.
Remuzgo-Martinez S, Atienza-Mateo B, Ocejo-Vinyals J, Pulito-Cueto V, Prieto-Pena D, Genre F . HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine. 2020; 88(3):105115. DOI: 10.1016/j.jbspin.2020.105115. View